COVID-19 disruption to cervical cancer screening in England
Journal of Medical Screening · 2022-09 · 29 (3) · 203-208
DOI: 10.1177/09691413221090892 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Screening, online erschienen am 04.04.2022. Verfasst von Alejandra Castanon und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer & Pharmaceutical Sciences, 4616King's College London, London, UK. Hauptthemen laut MEDLINE: COVID-19, Uterine Cervical Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
Introduction
In England, routine invitations for cervical screening were reduced between April 2020 and June 2020 due to the COVID-19 pandemic. We quantify the impact of COVID-19 disruptions on attendance and excess diagnoses of cervical cancer (CC).
Methods
Using Public Health England CC screening data on laboratory samples received in 2018 as a baseline we quantify the reduction in screening attendances due to the COVID-19 pandemic between April 2020 and March 2021 for women aged 25–64. We model the impact on excess CC diagnoses assuming once invitations resume 87.5% of women attend within 12 months and 12.5% delay screening for 3 or 5 years (depending on age).
Results
The number of samples received at laboratories was 91% lower than expected during April, 85% during May and 43% during June 2020 compared to the same period in 2018. Although on average laboratories received 12.6% more samples between August 2020 and April 2021 than over the same months in 2018, by April 2021 there was a short fall of 200,949 samples (6.4% fewer than in 2018). An excess of 41 CC (4.0 per 100,000 women with a maximum screening delay of 12 months) are predicted to occur among the estimated 1,024,794 women attending this screening round with a delay. An excess of 60 CC (41.0 per 100,000 women) are predicted to occur among the estimated 146,391 women who do not attend this screening round.
Conclusion
Prompt restoration of cervical screening services limited the impact on excess CC diagnoses. However, in 2020 a 6.4% shortfall of screening samples was observed. Every effort should be made to reassure these women that services are open and safe to attend.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Cancer & Pharmaceutical Sciences, 4616King's College London, London, UK.
- Screening Quality Assurance Service, NHS England and NHS Improvement, London, UK.
- Public Health Commissioning and Operations, NHS England and NHS Improvement, London, UK.
ORCID-Profile: Alejandra Castanon, Matejka Rebolj
Förderung
- Cancer Research UK
Zitieren
APA
Castanon, A., Rebolj, M., Pesola, F., Pearmain, P., & Stubbs, R. (2022). COVID-19 disruption to cervical cancer screening in England. Journal of Medical Screening, 29(3), 203-208. https://doi.org/10.1177/09691413221090892
Vancouver
Castanon A, Rebolj M, Pesola F, Pearmain P, Stubbs R. COVID-19 disruption to cervical cancer screening in England. Journal of Medical Screening. 2022;29(3):203-208. doi:10.1177/09691413221090892
BibTeX
@article{Castanon2022,
author = {Castanon, Alejandra and Rebolj, Matejka and Pesola, Francesca and Pearmain, Philippa and Stubbs, Ruth},
title = {COVID-19 disruption to cervical cancer screening in England},
journal = {Journal of Medical Screening},
year = {2022},
volume = {29},
number = {3},
pages = {203--208},
doi = {10.1177/09691413221090892}
}
EUVIMED